Immunologic and hematopoietic effects of CD40 stimulation after syngeneic bone marrow transplantation in mice

S Funakoshi1, D D Taub, M R Anver

  • 1Laboratory of Leukocyte Biology, National Cancer Institute, Frederick Cancer Research and Development Center (NCI-FCRDC), Maryland 21702, USA.

Insights

Stimulating CD40 with its ligand in mice after bone marrow transplantation significantly boosted B cell recovery and function. This treatment also accelerated hematopoietic recovery, improving granulocyte and platelet levels.

Area of Science:

  • Immunology
  • Hematology
  • Transplantation Science

Background:

  • CD40 molecule is crucial for B cell differentiation and activation in vitro.
  • Limited understanding of CD40 stimulation effects in vivo.
  • Investigating CD40 ligand's role in augmenting B cell recovery post-bone marrow transplantation (BMT).

Purpose of the Study:

  • To examine the effects of CD40 stimulation in a murine BMT model.
  • To assess the potential of soluble recombinant murine CD40 ligand (srmCD40L) in enhancing immune and hematopoietic recovery.

Main Methods:

  • Utilized a syngeneic bone marrow transplantation model in mice.
  • Administered srmCD40L intraperitoneally twice weekly post-BMT.
  • Analyzed B cell progenitors, serum immunoglobulin, splenic mitogen responsiveness, lymphoid organ repopulation, T cell responsiveness, and hematopoietic progenitor cells.

Main Results:

  • Increased B cell progenitors (B220+/surface IgM-) in bone marrow.
  • Enhanced B cell function, evidenced by increased serum immunoglobulin and LPS responsiveness.
  • Accelerated germinal center formation and promoted secondary lymphoid organ repopulation.
  • Demonstrated hematopoietic effects, including increased hematopoietic progenitor cells and accelerated granulocyte and platelet recovery.
  • In vitro incubation showed direct proliferative effects on hematopoietic progenitor cells.

Conclusions:

  • CD40 stimulation via srmCD40L accelerates immune recovery, particularly B cell reconstitution and function.
  • srmCD40L treatment also enhances hematopoietic recovery post-BMT, suggesting direct effects on progenitors.
  • CD40 ligand stimulation holds promise for improving patient outcomes following bone marrow transplantation.

Related Concept Videos